Last €27.75 EUR
Change Today +0.67 / 2.47%
Volume 200.0
KO2 On Other Exchanges
Symbol
Exchange
EN Paris
Berlin
OTC US
As of 10:51 AM 10/23/14 All times are local (Market data is delayed by at least 15 minutes).

korian-medica (KO2) Snapshot

Open
€27.35
Previous Close
€27.08
Day High
€27.75
Day Low
€27.18
52 Week High
09/22/14 - €30.00
52 Week Low
12/19/13 - €20.25
Market Cap
2.2B
Average Volume 10 Days
75.0
EPS TTM
--
Shares Outstanding
79.0M
EX-Date
07/3/14
P/E TM
--
Dividend
€0.60
Dividend Yield
2.16%
Current Stock Chart for KORIAN-MEDICA (KO2)

Related News

No related news articles were found.

korian-medica (KO2) Related Businessweek News

No Related Businessweek News Found

korian-medica (KO2) Details

Korian-Medica provides temporary and permanent dependency care services in France, Germany, Belgium, and Italy. As of April 30, 2014, it managed 506 nursing homes; and 87 specialised post-acute care clinics, which has approximately 2,400 beds in intermediate residences, as well as provides homecare and residences services. The company also operates retirement homes, médicalisées, and rehabilitation and psychiatric clinics. Korian-Medica was founded in 2001 and is based in Paris, France.

40,000 Employees
Last Reported Date: 09/24/14
Founded in 2001

korian-medica (KO2) Top Compensated Officers

Chief Executive Officer and Managing Director
Total Annual Compensation: €654.0K
Managing Director of Operations and Member of...
Total Annual Compensation: €76.4K
Deputy Chief Executive Officer
Total Annual Compensation: €58.5K
Observer
Total Annual Compensation: €129.0K
Compensation as of Fiscal Year 2013.

korian-medica (KO2) Key Developments

Korian Medica Announces Consolidated Earnings Results for the First Half of 2014; Provides Pro Forma Revenue Guidance for the Year 2014 and 2017

Korian Medica announced consolidated earnings results for the first half of 2014. For the first half, the company reported revenues of EUR 953.0 million against EUR 655.3 million a year ago. EBITDAR was EUR 256.1 million against EUR 171.3 million a year ago. EBITDA was EUR 125.1 million against EUR 80.2 million a year ago. Operating income was EUR 72.6 million against EUR 48.3 million a year ago. Financial loss was EUR 44.2 million against EUR 21.1 million a year ago. Income before taxes was EUR 28.4 million against EUR 27.2 million a year ago. Net income was EUR 17.6 million against EUR 17.7 million a year ago. Net income (group share) was EUR 16.3 million against EUR 16.6 million a year ago. Net cash flow generated by the activity was EUR 42.9 million against EUR 35.4 million a year ago. The growth in revenues reflects a new stage in the development of the Group, which it achieved with the effective integration of Medica on April 1, 2014, following the merger approved on March 18, 2014 by the respective general assemblies of both companies. On pro forma basis, the company reported revenues of EUR 1,230.5 million, EBITDAR of EUR 331.2 million, EBITDA of EUR 166.5 million, operating income of EUR 107.5 million, financial loss of EUR 29.6 million, net income group share of EUR 48.9 million and current net income group share of EUR 52.9 million against revenues of EUR 1,186.8 million, EBITDAR of EUR 315.5 million, EBITDA of EUR 154.9 million, operating income of EUR 104.3 million, financial loss of EUR 33.7 million, net income group share of EUR 46.0 million and current net income group share of EUR 44.7 million a year ago. This operation is the culmination of nearly 10 years of profitable and uninterrupted growth. With target pro forma revenues of EUR 2.5 billion for 2014, the average annual growth rate in revenue over the period from 2005 to 2014 stands at 20%. Beyond these short-term prospects, the company is now more than ever confident of achieving target revenues of EUR 3 billion in 2017.

Korian-Medica, Board Meeting, Sep 10, 2014

Korian-Medica, Board Meeting, Sep 10, 2014. Agenda: To approve consolidated earnings results for the first half of 2014.

Korian-Medica Announces Consolidated Revenue Results and Unaudited Pro Forma Revenue Results for the Second Quarter and First Half of 2014

Korian-Medica announced consolidated revenues and unaudited pro forma revenues for the second quarter and first half of 2014. For the quarter, the group's consolidated revenues were EUR 605.7 million against EUR 354.9 million for the same period last year. The group's unaudited pro forma revenues were EUR 619.3 million against EUR 600.0 million for the same period last year. For the first half, the group's consolidated revenues were EUR 952.8 million, representing a significant increase of 45.4% against EUR 655.3 million for the same period last year. The group's unaudited pro forma revenues were EUR 1,230.4 million against EUR 1,186.8 million for the same period last year.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KO2:GR €27.75 EUR +0.67

KO2 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Curanum AG €3.57 EUR -0.088
Generale de Sante SA €16.13 EUR +0.02
Le Noble Age €19.25 EUR +0.26
Orpea €46.65 EUR -0.01
Rhoen Klinikum AG €23.13 EUR +0.192
View Industry Companies
 

Industry Analysis

KO2

Industry Average

Valuation KO2 Industry Range
Price/Earnings 30.9x
Price/Sales 0.9x
Price/Book 0.8x
Price/Cash Flow 19.1x
TEV/Sales 0.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KORIAN-MEDICA, please visit www.groupe-korian.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.